Benjamin T. Dake, SEE REMARKS at Aerovate Therapeutics, Inc. (AVTE), sold 2,059 shares at $30.26 ($61K) on 2022-12-12, disclosed to the SEC on 2022-12-14.
Scheduled sale ($61k) by SEE REMARKS under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $25.82 | 20 | $516 | 0.9% |
| 2 | $28.83 | 1,132 | $33K | 53.9% |
| 3 | $30.26 | 907 | $27K | 45.3% |
| Total | $29.43 avg | 2,059 | $61K | 100% |
| Filing → |
| AVTE | SELL | 2024-03-28 | $619K | — | Filing → |
| AVTE | SELL | 2024-03-27 | $192K | — | Filing → |
| AVTE | SELL | 2024-03-20 | $1.8M | — | Filing → |